Patient characteristics
| Patient no. . | Age, y . | Sex . | Diagnosis . | Disease status . | Conditioning . | MUD vs MSD . | CD34+ dose (×106/kg) . | Day to engraftmen‡ . | CMV status . | Immunosuppression . | Antivirals§ . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 06213 | 35 | F | AML | CR1 | Flu/Mel | MSD | 8.5 | 13 | Positive | CSA | — |
| 0702 | 56 | M | MDS/AML | PR | Flu/Mel/alemtuzumab† | MUD | 8.7 | 24 | Positive | CSA/Pred | — |
| 06205 | 51 | F | ALL | CR1 | Cy/TBI | MSD | 2.6 | 26 | Positive | CSA/Pred | — |
| 0735 | 19 | F | ALL | CR2 | Cy/MESNA/TBI | MSD | 4.4 | 17 | Negative | CSA | — |
| 0743 | 65 | M | CML | CP2* | Flu/Mel | MSD | 3.7 | 27 | Positive | CSA | — |
| 0775 | 54 | M | AML | CR2 | Flu/Mel/ATG† | MUD | 6.9 | 17 | Negative | CSA/Pred | — |
| 0786 | 19 | M | AML | CR2 | Bu/Cy | MSD | 6 | 18 | Positive | CSA | — |
| 07110 | 39 | M | AML | CR1 | Bu/Cy | MSD | 3.3 | 26 | Positive | CSA/Pred | Val |
| 07141 | 49 | M | AML | CR1 | Bu/Cy | MSD | 2.1 | 14 | Negative | CSA | — |
| 07143 | 18 | M | AML | CR1 | Flu/Mel/alemtuzumab† | MUD | 4.6 | 14 | Positive | CSA | Foscarnet |
| 07138 | 39 | F | AML | CR1 | Cy/TBI/ATG† | MUD | 2.1 | 22 | Positive | CSA/Pred | — |
| 07169 | 51 | M | AML | CR1* | Flu/Mel | MSD | 4.4 | 30 | Positive | CSA | — |
| Patient no. . | Age, y . | Sex . | Diagnosis . | Disease status . | Conditioning . | MUD vs MSD . | CD34+ dose (×106/kg) . | Day to engraftmen‡ . | CMV status . | Immunosuppression . | Antivirals§ . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 06213 | 35 | F | AML | CR1 | Flu/Mel | MSD | 8.5 | 13 | Positive | CSA | — |
| 0702 | 56 | M | MDS/AML | PR | Flu/Mel/alemtuzumab† | MUD | 8.7 | 24 | Positive | CSA/Pred | — |
| 06205 | 51 | F | ALL | CR1 | Cy/TBI | MSD | 2.6 | 26 | Positive | CSA/Pred | — |
| 0735 | 19 | F | ALL | CR2 | Cy/MESNA/TBI | MSD | 4.4 | 17 | Negative | CSA | — |
| 0743 | 65 | M | CML | CP2* | Flu/Mel | MSD | 3.7 | 27 | Positive | CSA | — |
| 0775 | 54 | M | AML | CR2 | Flu/Mel/ATG† | MUD | 6.9 | 17 | Negative | CSA/Pred | — |
| 0786 | 19 | M | AML | CR2 | Bu/Cy | MSD | 6 | 18 | Positive | CSA | — |
| 07110 | 39 | M | AML | CR1 | Bu/Cy | MSD | 3.3 | 26 | Positive | CSA/Pred | Val |
| 07141 | 49 | M | AML | CR1 | Bu/Cy | MSD | 2.1 | 14 | Negative | CSA | — |
| 07143 | 18 | M | AML | CR1 | Flu/Mel/alemtuzumab† | MUD | 4.6 | 14 | Positive | CSA | Foscarnet |
| 07138 | 39 | F | AML | CR1 | Cy/TBI/ATG† | MUD | 2.1 | 22 | Positive | CSA/Pred | — |
| 07169 | 51 | M | AML | CR1* | Flu/Mel | MSD | 4.4 | 30 | Positive | CSA | — |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; Bu, busulphan; CML, chronic myeloid leukemia; CP2, second chronic phase; CR, complete remission; CSA, cyclosporine A; Cy, cyclophosphamide; Flu, fludarabine; MDS, myelodysplastic syndrome; Mel, melphalan; MSD, matched sibling donor; MUD, matched unrelated donor; PR, partial remission; Pred, prednisolone; TBI, total body irradiation; and Val, valaciclovir.
Second transplantation after prior allogeneic transplantation for CML.
In vivo T-cell depletion included antithymocyte globulin or alemtuzumab as part of the conditioning regimen in 4 patients.
The days to neutrophil engraftment, defined as a peripheral blood neutrophil count greater than 109/L on 2 or more successive days.
Therapeutic antivirals, excluding standard prophylactic valaciclovir 500 mg/day given from day 1 after HSCT until immune reconstitution. All patients were receiving prophylactic valaciclovir at the time of infusion except patients 07110 and 07143 who were receiving valaciclovir 2 g four times per day and therapeutic foscarnet, respectively.